Sanofi Aktie

86,10EUR
+1,09EUR
+1,28%
19:15:05
85,52EUR
+0,24EUR
+0,28%
17:50:06

WKN: 920657 / ISIN: FR0000120578

  Kaufen  
Verkaufen
oder
Werbung

Sanofi Aktien News

07:00 Uhr
Second Dupixent® (dupilumab) Phase 3 eosinophilic esophagitis trial to demonstrate significant disease improvements, underscoring role of type 2 inflammation in this complex disease (EN, Sanofi-Aventis)
07:00 UhrSecond Dupixent® (dupilumab) Phase 3 eosinophilic esophagitis trial to demonstrate significant disease improvements, underscoring role of type 2 inflammation in this complex disease (GlobeNewswire)
06:00 Uhr
Sanofi : Second Dupixent® (dupilumab) Phase 3 eosinophilic esophagitis trial to demonstrate significant disease improvements, underscoring role of type 2 inflammation in this complex disease (Investegate)
22.10.21
Dupixent® (dupilumab) is the first biologic to significantly reduce itch and skin lesions in Phase 3 trial for prurigo nodularis, demonstrating the role of type 2 inflammation in this disease (EN, Sanofi-Aventis)
22.10.21Dupixent® (dupilumab) is the first biologic to significantly reduce itch and skin lesions in Phase 3 trial for prurigo nodularis, demonstrating the role of type 2 inflammation in this disease (GlobeNewswire)
20.10.21
FDA expands approval of Dupixent® (dupilumab) to include children aged 6 to 11 years with moderate-to-severe asthma (EN, Sanofi-Aventis)
20.10.21FDA expands approval of Dupixent® (dupilumab) to include children aged 6 to 11 years with moderate-to-severe asthma (GlobeNewswire)
19.10.21
Oxford Biomedica PLC : Boehringer Ingelheim Exercises Option (Investegate)
13.10.21
New long-term data reinforcing promising safety and efficacy profile of brain-penetrant tolebrutinib presented at ECTRIMS 2021  (EN, Sanofi-Aventis)
13.10.21New long-term data reinforcing promising safety and efficacy profile of brain-penetrant tolebrutinib presented at ECTRIMS 2021  (GlobeNewswire)
13.10.21
Sanofi : New long-term data reinforcing promising safety and efficacy profile of brain-penetrant tolebrutinib presented at ECTRIMS 2021  (Investegate)
12.10.21
Update from Sanofi regarding Kevzara® (sarilumab): Supply constraints anticipated until early 2022 (EN, Sanofi-Aventis)
07.10.21
Sanofi: Positive results from the first study of high-dose influenza vaccine with a COVID-19 mRNA booster support co-administration recommendations (EN, Sanofi-Aventis)
01.10.21
The Zacks Analyst Blog Highlights: Pfizer, Novo Nordisk and Sanofi (Zacks)
30.09.21
New, late-breaking data at EADV highlights emerging clinical profile of amlitelimab (formerly KY1005) in adults with inadequately controlled moderate-to-severe atopic dermatitis (EN, Sanofi-Aventis)
30.09.21New, late-breaking data at EADV highlights emerging clinical profile of amlitelimab (formerly KY1005) in adults with inadequately controlled moderate-to-severe atopic dermatitis (GlobeNewswire)
30.09.21
Sanofi : New, late-breaking data at EADV highlights emerging clinical profile of amlitelimab (formerly KY1005) in adults with inadequately controlled moderate-to-severe atopic dermatitis (Investegate)
29.09.21
Are Investors Undervaluing Sanofi (SNY) Right Now? (Zacks)
29.09.21
Sanofi (SNY) Ends mRNA COVID Vaccine Bid Despite Positive Data (Zacks)
29.09.21
France Stops Development of Sanofi mRNA Vaccine against Covid (Novinite)
28.09.21
Sanofi to focus its COVID-19 development efforts on the recombinant vaccine candidate (EN, Sanofi-Aventis)
28.09.21
Sanofi drops plans for messenger RNA vaccine against virus (EN, Chinapost)
28.09.21
Sanofi stops development of Covid vaccine based on mRNA technology (Financial Times)
28.09.21
Sanofi announces positive Phase 1/2 study interim results for its first mRNA-based vaccine candidate (EN, Sanofi-Aventis)
28.09.21Sanofi announces positive Phase 1/2 study interim results for its first mRNA-based vaccine candidate (GlobeNewswire)
28.09.21
Sanofi : Sanofi announces positive Phase 1/2 study interim results for its first mRNA-based vaccine candidate (Investegate)
27.09.21
New research presented at IDWeek 2021 reinforces Sanofi’s robust vaccines pipeline and commitment to advancing public health protection (EN, Sanofi-Aventis)
24.09.21Sanofi: Availability of the Q3 2021 Memorandum for modelling purposes (GlobeNewswire)
24.09.21
Sanofi: Availability of the Q3 2021 Memorandum for modelling purposes (EN, Sanofi-Aventis)
24.09.21
Sanofi : Sanofi: Availability of the Q3 2021 Memorandum for modelling purposes (Investegate)
22.09.21KADMON HOLDINGS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kadmon Holdings, Inc. - KDMN (PR Newswire)
21.09.21
New Dupixent® (dupilumab) data in patients as young as 6 years old with moderate-to-severe atopic dermatitis to be presented at WCPD and EADV (EN, Sanofi-Aventis)
21.09.21New Dupixent® (dupilumab) data in patients as young as 6 years old with moderate-to-severe atopic dermatitis to be presented at WCPD and EADV (GlobeNewswire)
21.09.21
Sanofi : New Dupixent® (dupilumab) data in patients as young as 6 years old with moderate-to-severe atopic dermatitis to be presented at WCPD and EADV (Investegate)
19.09.21
ESMO late-breaking data show Libtayo® (cemiplimab) and chemotherapy first-line treatment combination significantly improved overall survival in patients with advanced NSCLC (EN, Sanofi-Aventis)
19.09.21ESMO late-breaking data show Libtayo® (cemiplimab) and chemotherapy first-line treatment combination significantly improved overall survival in patients with advanced NSCLC (GlobeNewswire)
14.09.21Sanofi completes acquisition of Translate Bio, accelerating the application of mRNA in new vaccines and therapeutics (GlobeNewswire)
14.09.21
Sanofi completes acquisition of Translate Bio, accelerating the application of mRNA in new vaccines and therapeutics (EN, Sanofi-Aventis)
14.09.21
Sanofi : Sanofi completes acquisition of Translate Bio, accelerating the application of mRNA in new vaccines and therapeutics (Investegate)
14.09.21
Beximco Pharmaceut : Sanofi Bangladesh Share Purchase Agreement signed (Investegate)
Seite: 123456789...18

Sanofi News

Sanofi News: auf dieser Seite finden Sie alle Sanofi News und Nachrichten zur Sanofi Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Sanofi News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Sanofi News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.
Werbung
finanzen.net zero
finanzen.net zero

Oskar

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
Zur klassischen Ansicht wechseln